Figure 7.

The Gab1 MBD represses cell cycle progression mediated by the oncogenic Met receptor. Oocytes were injected with optimal levels of Tpr-Met RNA (500 pg/oocyte) in the presence or absence of RNAs encoding wt or mutants forms of the Gab1 MBD (14 ng/oocyte). Histograms show the percentage of oocytes displaying GVBD, and the number of oocytes with visible GVBD over the number of oocytes injected is indicated above histogram bars. The data are representative of three independent experiments. Lysates prepared from oocytes were analyzed by immunoblot conducted with antibodies raised against the Met receptor, HA to detect HA-tagged MBD, phospho-MAPK, MAPK, phospho-JNK, or JNK1/2. MBD, wt, MBD of Gab1; MBDΔPI3K, mutant of the Gab1 MBD lacking the PI3K binding sites; MBDΔGrb2, mutant of the Gab1 MBD lacking Grb2 interaction site; MBDΔMBM, mutant of the Gab1 MBD lacking the MBM; and MBDΔMBMΔGrb2, mutant of the Gab1 MBD lacking the Grb2 and Met receptor binding sites.